{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:59:13Z","timestamp":1791845953968,"version":"4.3.4"},"reference-count":64,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.heliyon.2025.e41894","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T12:27:14Z","timestamp":1736512034000},"page":"e41894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Drug repurposing of argatroban, glimepiride and ranolazine shows anti-SARS-CoV-2 activity via diverse mechanisms"],"prefix":"10.1016","volume":"11","author":[{"given":"Shereen A.","family":"El Sobky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4543-119X","authenticated-orcid":false,"given":"Injie O.","family":"Fawzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud S.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Ragheb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merna H.M.","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan","family":"Bahaaeldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma A.","family":"Fahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3031-8932","authenticated-orcid":false,"given":"Ziad A.","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara H.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2878-5714","authenticated-orcid":false,"given":"Ahmed","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham A.","family":"Sadek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"El-Ekiaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed I.","family":"Abdelaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2025.e41894_bib1","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","article-title":"A novel coronavirus outbreak of global health concern","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2025.e41894_bib2","unstructured":"COVID - Coronavirus Statistics - Worldometer, 2023 (n.d.). https:\/\/www.worldometers.info\/coronavirus\/(accessed October 3, 2023)."},{"key":"10.1016\/j.heliyon.2025.e41894_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115503","article-title":"Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China","volume":"257","author":"Yang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.heliyon.2025.e41894_bib4","article-title":"Diabetes is a risk factor for the progression and prognosis of COVID-19","volume":"e3319","author":"Guo","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.heliyon.2025.e41894_bib5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2020.04.006","article-title":"Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan","volume":"146","author":"Li","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.heliyon.2025.e41894_bib6","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.annonc.2020.03.296","article-title":"Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China","volume":"31","author":"Zhang","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.heliyon.2025.e41894_bib7","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/all.14657","article-title":"Risk factors for severe and critically ill COVID\u201019 patients: a review","volume":"76","author":"Gao","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.heliyon.2025.e41894_bib8","unstructured":"COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.Available at: https:\/\/www.covid19treatmentguidelines.nih.gov\/, National Institutes of Health (n.d.). https:\/\/www.covid19treatmentguidelines.nih.gov\/(accessed May 31, 2023)."},{"key":"10.1016\/j.heliyon.2025.e41894_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261045","article-title":"Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons","volume":"17","author":"Tzou","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2025.e41894_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1132501","article-title":"Therapeutic developments for SARS-CoV-2 infection\u2014molecular mechanisms of action of antivirals and strategies for mitigating resistance in emerging variants in clinical practice","volume":"14","author":"S\u0103ndulescu","year":"2023","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.heliyon.2025.e41894_bib11","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2025.e41894_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/v13010003","article-title":"Natural selection plays an important role in shaping the codon usage of structural genes of the viruses belonging to the Coronaviridae family","volume":"13","author":"Nyayanit","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.heliyon.2025.e41894_bib13","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1016\/j.csbj.2021.08.029","article-title":"Co-crystallization and structure determination: an effective direction for anti-SARS-CoV-2 drug discovery","volume":"19","author":"Wang","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.heliyon.2025.e41894_bib14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2025.e41894_bib15","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","volume":"17","author":"Tai","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"7807 581","key":"10.1016\/j.heliyon.2025.e41894_bib16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2025.e41894_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114614","article-title":"FDA approved drugs with antiviral activity against SARS-CoV-2: from structure-based repurposing to host-specific mechanisms","volume":"162","author":"Ahmed","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.heliyon.2025.e41894_bib18","doi-asserted-by":"crossref","DOI":"10.1021\/ci600406v","article-title":"Solvated Interaction Energy (SIE) for scoring protein-ligand binding affinities. 1. Exploring the parameter space","volume":"47","author":"Na\u00efm","year":"2007","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.heliyon.2025.e41894_bib19","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2016265118","article-title":"Identification of tetracycline combinations as EphB1 tyrosine kinase inhibitors for treatment of neuropathic pain","volume":"118","author":"Ahmed","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.heliyon.2025.e41894_bib20","article-title":"Biological screening of cucurbitacin inspired estrone analogs targeting mitogen-activated protein kinase (MAPK) pathway","volume":"2017","author":"Ahmed","year":"2017","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.heliyon.2025.e41894_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2022.113244","article-title":"The spike-ACE2 binding assay: an in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies","volume":"503","author":"Zhang","year":"2022","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.heliyon.2025.e41894_bib22","doi-asserted-by":"crossref","DOI":"10.1101\/pdb.prot087379","article-title":"Crystal violet assay for determining viability of cultured cells","volume":"2016","author":"Feoktistova","year":"2016","journal-title":"Cold Spring Harb. Protoc."},{"key":"10.1016\/j.heliyon.2025.e41894_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph13120443","article-title":"FDA-approved drugs with potent in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2","volume":"13","author":"Mostafa","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.heliyon.2025.e41894_bib24","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3390\/ph13120443","article-title":"FDA-approved drugs with potent in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2","volume":"13","author":"Mostafa","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.heliyon.2025.e41894_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/MRA.00489-20","article-title":"Coding-complete genome sequences of two SARS-CoV-2 isolates from Egypt","volume":"9","author":"Kandeil","year":"2020","journal-title":"Microbiol Resour Announc"},{"key":"10.1016\/j.heliyon.2025.e41894_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2022.893634","article-title":"Antiviral activity of selected lamiaceae essential oils and their monoterpenes against SARS-cov-2","volume":"13","author":"\u0106avar Zeljkovi\u0107","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2025.e41894_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.05.024","article-title":"Investigation of flexibility of neuraminidase 150-loop using tamiflu derivatives in influenza A viruses H1N1 and H5N1","volume":"27","author":"Zima","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.heliyon.2025.e41894_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104528","article-title":"VE607 stabilizes SARS-CoV-2 Spike in the \u201cRBD-up\u201d conformation and inhibits viral entry","volume":"25","author":"Ding","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.heliyon.2025.e41894_bib29","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/1753-0407.13135","article-title":"The potential effects of clinical antidiabetic agents on SARS-CoV-2","volume":"13","author":"Qu","year":"2021","journal-title":"J. Diabetes"},{"key":"10.1016\/j.heliyon.2025.e41894_bib30","unstructured":"A. Barik, A. Das, P. Sasmal, Reprofiling the Antidiabetic Drugs to Restrict SARS-CoV-2: An In-Silico Approach,(n.d.). http:\/\/davapc1.bioch.dundee.ac.uk\/cgi-bin\/prodrg (accessed May 10, 2024)."},{"key":"10.1016\/j.heliyon.2025.e41894_bib31","doi-asserted-by":"crossref","DOI":"10.3906\/biy-2012-52","article-title":"In silico drug repositioning against human nrp1 to block sars-cov-2 host entry","volume":"45","author":"G\u00fcl","year":"2021","journal-title":"Turk. J. Biol."},{"key":"10.1016\/j.heliyon.2025.e41894_bib32","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2125.2011.03916.x","article-title":"Direct thrombin inhibitors","volume":"72","author":"Lee","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.heliyon.2025.e41894_bib33","doi-asserted-by":"crossref","DOI":"10.1007\/s10557-020-07066-x","article-title":"Thrombin inhibition by argatroban: potential therapeutic benefits in COVID-19","volume":"35","author":"Aliter","year":"2021","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.heliyon.2025.e41894_bib34","doi-asserted-by":"crossref","DOI":"10.1099\/jgv.0.001135","article-title":"Evaluation of anticoagulant agents for the treatment of human metapneumovirus infection in mice","volume":"99","author":"L\u00ea","year":"2018","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.heliyon.2025.e41894_bib35","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/bph.14084","article-title":"Protease-activated receptor 1 inhibition protects mice against thrombin-dependent respiratory syncytial virus and human metapneumovirus infections","volume":"175","author":"L\u00ea","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.heliyon.2025.e41894_bib36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ijlh.13230","article-title":"Thromboembolic events and apparent heparin resistance in patients infected with SARS\u2010CoV\u20102","volume":"42","author":"Beun","year":"2020","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.heliyon.2025.e41894_bib37","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11239-020-02145-0","article-title":"Heparin resistance in COVID-19 patients in the intensive care unit","volume":"50","author":"White","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.heliyon.2025.e41894_bib38","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1111\/bjh.16927","article-title":"Anticoagulation with argatroban in patients with acute antithrombin deficiency in severe COVID-19","volume":"190","author":"Arachchillage","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.heliyon.2025.e41894_bib39","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11239-020-02251-z","article-title":"Argatroban for therapeutic anticoagulation for heparin resistance associated with Covid-19 infection","volume":"51","author":"McGlynn","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.heliyon.2025.e41894_bib40","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-020-02430-9","article-title":"Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19)","volume":"18","author":"Kim","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.heliyon.2025.e41894_bib41","unstructured":"H. Khadim Sheikh, T. Arshad, Z.S. Mohammad, I. Arshad, M. Hassan, REPURPOSED SINGLE INHIBITOR FOR SERINE PROTEASE AND SPIKE GLYCOPROTEINS OF SARS-CoV-2,(n.d.). https:\/\/doi.org\/doi:10.26434\/chemrxiv.12192660.v1Thiscontentisapreprintandhasnotbeenpeer-reviewed."},{"key":"10.1016\/j.heliyon.2025.e41894_bib42","author":"Duy Nguyen"},{"key":"10.1016\/j.heliyon.2025.e41894_bib43","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1586\/erc.11.91","article-title":"Ranolazine: an antianginal drug with antiarrhythmic properties","volume":"9","author":"Tamargo","year":"2011","journal-title":"Expert Rev. Cardiovasc Ther."},{"key":"10.1016\/j.heliyon.2025.e41894_bib44","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41591-022-01689-3","article-title":"Long-term cardiovascular outcomes of COVID-19","volume":"28","author":"Xie","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2025.e41894_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2021.110545","article-title":"COVID-19-related arrhythmias and the possible effects of ranolazine","volume":"149","author":"Chukwunyere","year":"2021","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.heliyon.2025.e41894_bib46","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s43044-021-00201-5","article-title":"Contemporary approach to understand and manage COVID-19-related arrhythmia","volume":"73","author":"Nabeh","year":"2021","journal-title":"The Egyptian Heart Journal"},{"key":"10.1016\/j.heliyon.2025.e41894_bib47","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2710.2006.00766.x","article-title":"Pharmacokinetic and pharmacodynamic modelling of the effects of glimepiride on insulin secretion and glucose lowering in healthy humans","volume":"31","author":"Yun","year":"2006","journal-title":"J. Clin. Pharm. Therapeut."},{"key":"10.1016\/j.heliyon.2025.e41894_bib48","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/bjh.18153","article-title":"How to dose and monitor argatroban for treatment of HIT","volume":"197","author":"Warkentin","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.heliyon.2025.e41894_bib49","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2165\/00003088-200645050-00003","article-title":"Clinical pharmacokinetics of ranolazine","volume":"45","author":"Jerling","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.heliyon.2025.e41894_bib50","doi-asserted-by":"crossref","first-page":"W513","DOI":"10.1093\/nar\/gkae303","article-title":"ProTox 3.0: a webserver for the prediction of toxicity of chemicals","volume":"52","author":"Banerjee","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.heliyon.2025.e41894_bib51","unstructured":"CHMP, LATIXA; INN: ranolazine, n.d http:\/\/www.emea.europa.eu."},{"key":"10.1016\/j.heliyon.2025.e41894_bib52","unstructured":"Paxlovid Drug-Drug Interactions | COVID-19 Treatment Guidelines,(n.d.). https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/antivirals-including-antibody-products\/ritonavir-boosted-nirmatrelvir--paxlovid-\/paxlovid-drug-drug-interactions\/(accessed November 21, 2023)."},{"issue":"4 52","key":"10.1016\/j.heliyon.2025.e41894_bib53","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4167\/jbv.2022.52.4.149","article-title":"In vitro antiviral activity of remdesivir against SARS-CoV-2 and its variants","volume":"52","author":"Nowakowska","year":"2022","journal-title":"J. Bacteriol. Virol."},{"key":"10.1016\/j.heliyon.2025.e41894_bib54","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.addr.2018.04.013","article-title":"Regulatory pitfalls and opportunities when repurposing for inhalation therapy","volume":"133","author":"Lyapustina","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.heliyon.2025.e41894_bib55","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.heliyon.2025.e41894_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107940","article-title":"Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice","volume":"32","author":"Pruijssers","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.heliyon.2025.e41894_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2423-5","article-title":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2","volume":"585","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2025.e41894_bib58","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2025.e41894_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104899","article-title":"Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: clinical outcome and differences in post-treatment hospitalisation status","volume":"158","author":"Antinori","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.heliyon.2025.e41894_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro","volume":"178","author":"Choy","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.heliyon.2025.e41894_bib61","unstructured":"M.D. Whittington, S.D. Pearson, D.M. Rind, J.D. Campbell, The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19, (n.d. https:\/\/doi.org\/10.1016\/j.jval.2."},{"key":"10.1016\/j.heliyon.2025.e41894_bib62","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01155-21","article-title":"Rethinking remdesivir: synthesis, antiviral activity, and pharmacokinetics of oral lipid prodrugs","volume":"65","author":"Schooley","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.heliyon.2025.e41894_bib63","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","article-title":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2","volume":"585","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2025.e41894_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.626553","article-title":"Animal models for COVID-19: hamsters, mouse, ferret, mink, tree shrew, and non-human primates","volume":"12","author":"Shou","year":"2021","journal-title":"Front. Microbiol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844025002749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844025002749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T12:43:35Z","timestamp":1775738615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844025002749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2405844025002749"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2025.e41894","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug repurposing of argatroban, glimepiride and ranolazine shows anti-SARS-CoV-2 activity via diverse mechanisms","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2025.e41894","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e41894"}}